Literature DB >> 17599050

RET(MEN 2B) is active in the endoplasmic reticulum before reaching the cell surface.

P Runeberg-Roos1, H Virtanen, M Saarma.   

Abstract

MEN 2B (multiple endocrine neoplasia type 2B) is an autosomal dominant cancer syndrome caused by an oncogenic form of the receptor tyrosine kinase REarranged during transfection (RET). The MEN 2B syndrome is associated with an abnormal autophosphorylation of the mutated receptor even without ligand-stimulation. Here, we characterize the activation of a RET(MEN 2B) variant carrying the point mutation Met918Thr, and show that the 150 kDa precursor of RET(MEN 2B) becomes phosphorylated already during synthesis in the endoplasmic reticulum (ER). At least three different tyrosine residues (Tyr905, Tyr1062, Tyr1096) of the RET(MEN 2B) precursor are phosphorylated before the oncogenic receptor reaches the cell surface. We also demonstrate that the precursor of RET(MEN 2B) interacts with both growth factor receptor-bound protein and Src homology 2 domain-containing already in the ER, and that this interaction is dependent on the kinase activity of RET. With the aid of two RET mutants (RET(MEN 2B/S32L) and RET(MEN 2B/F393L)), which accumulate in the ER, we show that the oncogenic precursor of the receptor has the capacity to activate AKT, extracellular signal-regulated kinase and signal transducer and activator of transcription 3 from the ER. Taken together, our data demonstrate that the oncogenic precursor of RET(MEN 2B) is phosphorylated, interacts with adapter proteins and induces downstream signalling from the ER.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17599050     DOI: 10.1038/sj.onc.1210591

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.

Authors:  David S Hong; Maria E Cabanillas; Jennifer Wheler; Aung Naing; Apostolia M Tsimberidou; Lei Ye; Naifa L Busaidy; Steven G Waguespack; Mike Hernandez; Adel K El Naggar; Alder K El Naggar; Savita Bidyasar; John Wright; Steven I Sherman; Razelle Kurzrock
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

2.  A direct role for Met endocytosis in tumorigenesis.

Authors:  Carine Joffre; Rachel Barrow; Ludovic Ménard; Véronique Calleja; Ian R Hart; Stéphanie Kermorgant
Journal:  Nat Cell Biol       Date:  2011-06-05       Impact factor: 28.824

Review 3.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

4.  Alternative splicing results in RET isoforms with distinct trafficking properties.

Authors:  Douglas S Richardson; David M Rodrigues; Brandy D Hyndman; Mathieu J F Crupi; Adrian C Nicolescu; Lois M Mulligan
Journal:  Mol Biol Cell       Date:  2012-08-08       Impact factor: 4.138

5.  Mitogen-activated protein kinase (MAPK) pathway regulates branching by remodeling epithelial cell adhesion.

Authors:  Anneliis Ihermann-Hella; Maria Lume; Ilkka J Miinalainen; Anniina Pirttiniemi; Yujuan Gui; Johan Peränen; Jean Charron; Mart Saarma; Frank Costantini; Satu Kuure
Journal:  PLoS Genet       Date:  2014-03-06       Impact factor: 5.917

6.  A Novel Small Molecule GDNF Receptor RET Agonist, BT13, Promotes Neurite Growth from Sensory Neurons in Vitro and Attenuates Experimental Neuropathy in the Rat.

Authors:  Yulia A Sidorova; Maxim M Bespalov; Agnes W Wong; Oleg Kambur; Viljami Jokinen; Tuomas O Lilius; Ilida Suleymanova; Gunnar Karelson; Pekka V Rauhala; Mati Karelson; Peregrine B Osborne; Janet R Keast; Eija A Kalso; Mart Saarma
Journal:  Front Pharmacol       Date:  2017-06-21       Impact factor: 5.810

7.  Small-Molecule Ligands as Potential GDNF Family Receptor Agonists.

Authors:  Larisa Ivanova; Jaana Tammiku-Taul; Yulia Sidorova; Mart Saarma; Mati Karelson
Journal:  ACS Omega       Date:  2018-01-25

8.  Development of the urogenital system is regulated via the 3'UTR of GDNF.

Authors:  Hao Li; Madis Jakobson; Roxana Ola; Yujuan Gui; Anmol Kumar; Petra Sipilä; Hannu Sariola; Satu Kuure; Jaan-Olle Andressoo
Journal:  Sci Rep       Date:  2019-03-28       Impact factor: 4.379

Review 9.  Multiple Endocrine Neoplasia Syndromes from Genetic and Epigenetic Perspectives.

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Biomark Insights       Date:  2018-07-02

Review 10.  Small Molecules and Peptides Targeting Glial Cell Line-Derived Neurotrophic Factor Receptors for the Treatment of Neurodegeneration.

Authors:  Yulia A Sidorova; Mart Saarma
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.